<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACTIVASE- alteplase 
			 </strong><br>Genentech, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ACTIVASE safely and effectively. See full prescribing information for ACTIVASE. <br><br>Activase (alteplase) for injection, for intravenous use <br>Initial U.S. Approval: 1987</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Activase is a tissue <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator (tPA) indicated for the treatment of </p>
<ul>
<li>Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span> (AIS). (<a href="#S1.1">1.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> (AMI) to reduce mortality and incidence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#S1.2">1.2</a>)<br><span class="Underline">Limitation of Use in AMI:</span> the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> may be greater than the benefit in patients at low risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from cardiac causes. (<a href="#S1.2">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Acute Massive Pulmonary Embolism</span> (PE) for lysis. (<a href="#S1.3">1.3</a>)</li>
</ul>
</div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>
<span class="Underline">Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></span>: The recommended dose is 0.9 mg/kg (not to exceed 90 mg total dose) infused intravenously over 60 minutes with 10% of the total dose administered as an initial bolus over 1 minute. (<a href="#S2.1">2.1</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span></span>: The recommended total dose is based on patient weight, not to exceed 100 mg. (<a href="#S2.2">2.2</a>)</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Acute Massive Pulmonary Embolism</span></span>: The recommended dose is 100 mg administered by IV infusion over 2 hours. (<a href="#S2.3">2.3</a>)</li>
<li>Do not add other medications to infusions containing Activase. (<a href="#S2.5">2.5</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Lyophilized powder: 50 mg and 100 mg with Sterile Water for Injection USP for reconstitution at 1 mg per 1 mL. (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta"><span class="Underline">General</span> </p>
<ul>
<li>Active internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#S4.1">4.1</a>, <a href="#S4.2">4.2</a>)</li>
<li>Recent intracranial or intraspinal surgery or serious head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. (<a href="#S4.1">4.1</a>, <a href="#S4.2">4.2</a>)</li>
<li>Intracranial conditions that may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#S4.1">4.1</a>, <a href="#S4.2">4.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> diathesis. (<a href="#S4.1">4.1</a>, <a href="#S4.2">4.2</a>)</li>
<li>Current severe <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>. (<a href="#S4.1">4.1</a>, <a href="#S4.2">4.2</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline">Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></span> </p>
<ul>
<li>Current <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>. (<a href="#S4.1">4.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">Subarachnoid hemorrhage</span>. (<a href="#S4.1">4.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline"><span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></span> </p>
<ul><li>History of recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. (<a href="#S4.2">4.2</a>)</li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Avoid intramuscular injections. Monitor for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs, discontinue Activase. (<a href="#S5.1">5.1</a>)</li>
<li>Monitor patients during and for several hours after infusion for orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> develops, discontinue Activase. (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> has been reported rarely in patients treated with thrombolytic agents. (<a href="#S5.3">5.3</a>)</li>
<li>Consider the risk of reembolization from the lysis of underlying deep venous thrombi in patients with <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>. (<a href="#S5.4">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most frequently occurring adverse reaction ( &gt; 5%) is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Anticoagulants and drugs that inhibit platelet function increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when administered with Activase therapy. (<a href="#S7">7</a>)</li>
<li>Concomitant angiotensin-converting enzyme inhibitors may increase the risk of orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. (<a href="#S7">7</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pregnancy: Activase is embryocidal in rabbits. (<a href="#S8.1">8.1</a>) </p></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE)</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation for Administration</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Administration</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS </a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">Cholesterol Embolization</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Reembolization of Deep Venous Thrombi during Treatment for <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Acute Massive Pulmonary Embolism</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Coagulation Tests May Be Unreliable during Activase Therapy</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2     Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3	Pharmacokinetics </a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1   Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span> (AIS)</a></h2>
<h2><a href="#section-12.2" class="toc">14.2	<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> (AMI)</a></h2>
<h2><a href="#section-12.3" class="toc">14.3	<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Acute Massive Pulmonary Embolism</span> (PE)</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2	Stability and Storage</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></h2>
<p class="First">Activase is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>.</p>
<p>Exclude <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> as the primary cause of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> signs and symptoms prior to initiation of treatment <span class="Italics">[see <a href="#S4.1">Contraindications (4.1)</a>]</span>. Initiate treatment as soon as possible but within 3 hours after symptom onset.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span></h2>
<p class="First">Activase is indicated for use in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (AMI) for the reduction of mortality and reduction of the incidence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.1"></a><p></p>
<p class="First"><span class="Underline">Limitation of Use:</span> The risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> may outweigh the benefit produced by thrombolytic therapy in patients whose AMI puts them at low risk for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></h2>
<p class="First">Activase is indicated for the lysis of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">acute massive pulmonary embolism</span>, defined as:</p>
<ul>
<li>Acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments.</li>
<li>Acute pulmonary emboli accompanied by unstable hemodynamics, e.g., failure to maintain blood pressure without supportive measures.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></h2>
<p class="First">Administer Activase as soon as possible but within 3 hours after onset of symptoms.</p>
<p>The recommended dose is 0.9 mg/kg (not to exceed 90 mg total dose), with 10% of the total dose administered as an initial intravenous bolus over 1 minute and the remainder infused over 60 minutes.</p>
<p>During and following Activase administration for the treatment of acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, frequently monitor and control blood pressure. </p>
<p>In patients without recent use of oral anticoagulants or heparin, Activase treatment can be initiated prior to the availability of coagulation study results. Discontinue Activase if the pretreatment International Normalized Ratio (INR) is greater than 1.7 or the <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT) is elevated <span class="Italics">[see <a href="#S4.1">Contraindications (4.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span></h2>
<p class="First">Administer Activase as soon as possible after the onset of symptoms.</p>
<p>The recommended total doses for <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (AMI) is based on patient weight, not to exceed 100 mg, regardless of the selected administration regimen (accelerated or 3 hour, described below). </p>
<p>There are two Activase dose regimens (accelerated and 3-hour) for use in the management of AMI; there are no controlled studies to compare clinical outcomes with these regimens <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Bold">Accelerated Infusion</span></p>
<p>The recommended accelerated infusion dose consists of an IV bolus <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>]</span> followed by an IV infusion as set forth in <a href="#table1">Table 1</a>.</p>
<a name="table1"></a><table width="80%">
<caption><span>Table 1 Accelerated Infusion Weight-Based Doses for Patients with AMI</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Patient weight</th>
<th align="center">Intravenous Bolus</th>
<th align="center">First 30 min</th>
<th class="Rrule" align="center">Next 60 min</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center">&gt; 67 kg</td>
<td align="center">15 mg</td>
<td align="center">50 mg</td>
<td class="Rrule" align="center">35 mg</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">≤ 67 kg</td>
<td align="center">15 mg</td>
<td align="center">0.75 mg/kg</td>
<td class="Rrule" align="center">0.50 mg/kg</td>
</tr>
</tbody>
</table>
<p>The safety and efficacy of accelerated infusion of Activase have only been investigated with concomitant administration of heparin and aspirin <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Bold">3-Hour Infusion</span></p>
<p>For patients weighing ≥ 65 kg, the recommended dose is 100 mg administered as 60 mg in the first hour (6-10 mg administered as a bolus), 20 mg over the second hour, and 20 mg over the third hour. For smaller patients (&lt; 65 kg), a dose of 1.25 mg/kg administered over 3 hours may be used. Weight-based doses are shown in <a href="#table2">Table 2</a>.</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2 3-hour Infusion Weight-Based Doses for Patients with AMI</span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom">Patient weight</th>
<th align="center" valign="bottom">Bolus</th>
<th align="center" valign="bottom">Rest of 1st hour</th>
<th align="center" valign="bottom">2nd hour</th>
<th class="Rrule" align="center" valign="bottom">3rd hour</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center">≥ 65 kg</td>
<td align="center">6-10 mg</td>
<td align="center">50-54 mg</td>
<td align="center">20 mg</td>
<td class="Rrule" align="center">20 mg</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">&lt; 65 kg</td>
<td align="center">0.075 mg/kg</td>
<td align="center">0.675 mg/kg</td>
<td align="center">0.25 mg/kg</td>
<td class="Rrule" align="center">0.25 mg/kg</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE)</h2>
<p class="First">The recommended dose is 100 mg administered by IV infusion over 2 hours.</p>
<p>Institute parenteral anticoagulation near the end of or immediately following the Activase infusion when the partial thromboplastin time or <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span> returns to twice normal or less.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation for Administration</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1"></a><p></p>
<p class="First"><span class="Bold">Reconstitution</span></p>
<p>Use only the accompanying Sterile Water for Injection (SWFI), USP without preservatives. Do not use Bacteriostatic Water for Injection, USP.</p>
<p>Reconstitute using aseptic technique. Do not add other medication to solutions containing Activase. Reconstitute Activase no more than 8 hours before use, as it contains no antibacterial preservatives <span class="Italics">[see <a href="#S16.2">How Supplied/Storage and Handling (16.2)</a>]</span>.</p>
<p>Slight foaming is not unusual; let stand undisturbed for several minutes to allow large bubbles to dissipate. Inspect parenteral drug products for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
<p>Activase may be administered as reconstituted at 1 mg/mL or further diluted immediately before administration in an equal volume of 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, to yield a concentration of 0.5 mg/mL, using either polyvinyl chloride bags or glass vials.</p>
<p>Avoid excessive <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> during dilution; mix by gently swirling and/or slow inversion.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1.1"></a><p></p>
<p class="First"><span class="Underline">50 mg Vials</span></p>
<dl>
<dt> </dt>
<dd>DO NOT USE IF VACUUM IS NOT PRESENT.</dd>
<dt> </dt>
<dd>Using a large bore needle (e.g., 18 gauge) and a syringe, reconstitute by adding the contents of the accompanying 50 mL vial of SWFI to the 50 mg vial of Activase, directing the SWFI stream into the lyophilized cake.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1.2"></a><p></p>
<p class="First"><span class="Underline">100 mg Vials</span></p>
<dl>
<dt> </dt>
<dd>THE 100 mg VIALS DO NOT CONTAIN VACUUM.</dd>
<dt> </dt>
<dd>Using the transfer device provided, reconstitute by adding the contents of the accompanying 100 mL vial of SWFI to the 100 mg vial of Activase. </dd>
</dl>
<ol>
<li>Use aseptic technique.</li>
<li>Remove the protective flip-caps from one vial of Activase and one vial of SWFI.</li>
<li>Open the package containing the transfer device by <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> the paper label off the package.</li>
<li>Remove the protective cap from one end of the transfer device and keeping the vial of SWFI upright, insert the piercing pin vertically into the center of the stopper of the vial of SWFI.</li>
<li>Remove the protective cap from the other end of the transfer device. <span class="Underline">DO NOT INVERT THE VIAL OF SWFI.</span>
</li>
<li>Hold the vial of Activase upside down, position it so that the center of the stopper is directly over the exposed piercing pin of the transfer device, and push the vial of Activase down so that the piercing pin is inserted through the center of the Activase vial stopper.</li>
<li>Invert the two vials so that the vial of Activase is on the bottom (upright) and the vial of SWFI is upside-down, allowing the SWFI to flow down through the transfer device. Allow the entire contents of the vial of SWFI to flow into the Activase vial (approximately 0.5 cc of SWFI will remain in the diluent vial).</li>
<li>Remove the transfer device and the empty SWFI vial from the Activase vial and discard.</li>
<li>Swirl gently to dissolve the Activase powder. <span class="Underline">DO NOT SHAKE.</span>
</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.2"></a><p></p>
<p class="First"><span class="Bold">Preparation of Bolus Dose</span></p>
<ul>
<li>Prepare the bolus dose in one of the following ways: Remove the appropriate volume from the vial of reconstituted (1 mg/mL) Activase using a syringe and needle. If this method is used with the 50 mg vials, the syringe should not be primed with air and the needle should be inserted into the Activase vial stopper. If the 100 mg vial is used, the needle should be inserted away from the puncture mark made by the transfer device.</li>
<li>Remove the appropriate volume from a port (second injection site) on the infusion line after the infusion set is primed.</li>
<li>Program an infusion pump to deliver the appropriate volume as a bolus at the initiation of the infusion</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Administration</h2>
<p class="First">Following bolus dose, if indicated <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1</a>, <a href="#S2.2">2.2)</a>]:</span></p>
<ul>
<li>
<span class="Underline">50 mg vials - </span>administer using either a polyvinyl chloride bag or glass vial and infusion set.</li>
<li>
<span class="Underline">100 mg vials - </span>remove from the vial any quantity of drug in excess of that specified for patient treatment <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1</a>, <a href="#S2.2">2.2)</a>]</span>. Insert the spike end of an infusion set through the same puncture site created by the transfer device in the stopper of the vial of reconstituted Activase. Peel the clear plastic hanger from the vial label. Hang the Activase vial from the resulting loop.</li>
</ul>
<p>Activase is for intravenous administration only. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of Activase infusion can cause <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. If <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occurs, terminate the infusion at that IV site and apply local therapy.</p>
<p>Do not add any other medication to infusion solutions containing Activase.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS </h1>
<ul>
<li>50 mg lyophilized powder per single use vial with 50 mL SWFI USP for reconstitution</li>
<li>100 mg lyophilized powder per single use vial with 100 mL SWFI USP for reconstitution</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></h2>
<p class="First">Do not administer Activase to treat acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> in the following situations in which the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is greater than the potential benefit <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>:</p>
<ul>
<li>Current <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> </li>
<li><span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">Subarachnoid hemorrhage</span></li>
<li>Active internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>Recent (within 3 months) intracranial or intraspinal surgery or serious head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span></li>
<li>Presence of intracranial conditions that may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (e.g., some neoplasms, <span class="product-label-link" type="condition" conceptid="4075418" conceptname="Arteriovenous malformation">arteriovenous malformations</span>, or <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysms</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> diathesis</li>
<li>Current severe <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></h2>
<p class="First">Do not administer Activase for treatment of AMI or PE in the following situations in which the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is greater than the potential benefit<span class="Italics"> [see <a href="#S5.1">Warnings and Precautions (5.1)</a>]:</span></p>
<ul>
<li>Active internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>History of recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>Recent (within 3 months) intracranial or intraspinal surgery or serious head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span></li>
<li>Presence of intracranial conditions that may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (e.g. some neoplasms, <span class="product-label-link" type="condition" conceptid="4075418" conceptname="Arteriovenous malformation">arteriovenous malformations</span>, or <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysms</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> diathesis</li>
<li>Current severe <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Activase can cause internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (intracranial, retroperitoneal, gastrointestinal, genitourinary, respiratory) or external <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, especially at arterial and venous puncture sites. Avoid intramuscular injections and <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> to the patient while on Activase. Perform venipunctures carefully and only as required. To minimize <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from noncompressible sites, avoid internal jugular and subclavian venous punctures. If an arterial puncture is necessary during Activase infusion, use an upper extremity vessel that is accessible to manual compression, apply pressure for at least 30 minutes, and monitor the puncture site closely.</p>
<p>Because of the higher risk of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> in patients treated for acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, limit treatment to facilities that can provide timely access to appropriate evaluation and management of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.</p>
<p>Fatal cases of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> associated with traumatic intubation in patients administered Activase have been reported.</p>
<p>Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, but the concomitant administration of heparin and aspirin with and following infusions of Activase for the treatment of acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> during the first 24 hours after symptom onset has not been investigated. Because heparin, aspirin, or Activase may cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications, carefully monitor for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, especially at arterial puncture sites. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> can occur 1 or more days after administration of Activase, while patients are still receiving anticoagulant therapy.</p>
<p>If serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs, terminate the Activase infusion. </p>
<p>In the following conditions, the risks of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with Activase therapy for all approved indications are increased and should be weighed against the anticipated benefits:</p>
<ul>
<li>Recent major surgery or procedure, (e.g., coronary artery bypass graft, obstetrical delivery, organ biopsy, previous puncture of noncompressible vessels)</li>
<li>Cerebrovascular disease</li>
<li>Recent <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span></li>
<li>Recent gastrointestinal or genitourinary <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>Recent <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span></li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: systolic BP above 175 mm Hg or diastolic BP above 110 mm Hg</li>
<li>High likelihood of left heart thrombus, e.g., <span class="product-label-link" type="condition" conceptid="315273" conceptname="Mitral valve stenosis">mitral stenosis</span> with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span></li>
<li><span class="product-label-link" type="condition" conceptid="320116" conceptname="Acute pericarditis">Acute pericarditis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4249899" conceptname="Subacute bacterial endocarditis">Subacute bacterial endocarditis</span></li>
<li>Hemostatic defects including those secondary to severe hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span></li>
<li>Significant hepatic dysfunction</li>
<li>Pregnancy</li>
<li>Diabetic hemorrhagic <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, or other hemorrhagic ophthalmic conditions</li>
<li>Septic <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or occluded AV cannula at seriously infected site</li>
<li>Advanced age <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>
</li>
<li>Patients currently receiving anticoagulants (e.g., warfarin sodium)</li>
<li>Any other condition in which <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> constitutes a significant hazard or would be particularly difficult to manage because of its location.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h2>
<p class="First">Orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has been observed during and up to 2 hours after Activase infusion in patients treated for acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. In many cases, patients received concomitant angiotensin-converting enzyme inhibitors <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]. </span>Monitor patients treated with Activase during and for several hours after infusion for orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">Cholesterol Embolization</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> has been reported rarely in patients treated with thrombolytic agents; the true incidence is unknown. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> may present with <span class="product-label-link" type="condition" conceptid="4081096" conceptname="Livedo reticularis">livedo reticularis</span>, "purple toe" syndrome, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, gangrenous digits, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span>, <span class="product-label-link" type="condition" conceptid="4269209" conceptname="Acute infarction of spinal cord">spinal cord infarction</span>, <span class="product-label-link" type="condition" conceptid="4334245" conceptname="Retinal artery occlusion">retinal artery occlusion</span>, bowel <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, or <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> and can be fatal. It is associated with invasive vascular procedures (e.g., cardiac catheterization, angiography, vascular surgery) and/or anticoagulant therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Reembolization of Deep Venous Thrombi during Treatment for <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Acute Massive Pulmonary Embolism</span></h2>
<p class="First">Activase has not been shown to treat adequately underlying <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in patients with PE. Consider the possible risk of reembolization due to the lysis of underlying deep venous thrombi in this setting.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Coagulation Tests May Be Unreliable during Activase Therapy</h2>
<p class="First">Coagulation tests and measures of fibrinolytic activity may be unreliable during Activase therapy, unless specific precautions are taken to prevent in vitro artifacts. When present in blood at pharmacologic concentrations, Activase remains active under in vitro conditions, which can result in degradation of fibrinogen in blood samples removed for analysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in the other sections of the label:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">Cholesterol Embolization</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Reembolization of Deep Venous Thrombi during Treatment for <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Acute Massive Pulmonary Embolism</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>].</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The most frequent adverse reaction associated with Activase in all approved indications is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span> (AIS)</span></p>
<p>In clinical studies in patients with AIS (Studies 1 and 2) the incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, especially symptomatic <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, was higher in Activase-treated patients than in placebo patients.  A dose-finding study of Activase suggested that doses greater than 0.9 mg/kg may be associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.</p>
<p>The incidence of all-cause 90-day mortality, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, and new <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> following Activase treatment compared to placebo are presented in <a href="#table3">Table 3</a> as a combined safety analysis (n=624) for Studies 1 and 2.  These data indicate a significant increase in <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> following Activase treatment, particularly symptomatic <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> within 36 hours.  There was no increase in the incidences of 90-day mortality or severe <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> in Activase-treated patients compared to placebo.</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3 Combined Safety Outcomes for Studies 1 and 2</span></caption>
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="center"></th>
<th align="center">Placebo<br>(n= 312)</th>
<th align="center">Activase<br>(n=312)</th>
<th class="Rrule" align="center">
<br>p-Value<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Fisher's Exact Test.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Within trial follow-up period.  Symptomatic <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> was defined as the occurrence of sudden clinical worsening followed by subsequent verification of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> on CT scan.  Asymptomatic <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> was defined as <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> detected on a routine repeat CT scan without preceding clinical worsening.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="center">All-Cause 90-day Mortality</td>
<td align="center">64 (20.5%)</td>
<td align="center">54 (17.3%) 															</td>
<td class="Rrule" align="center">0.36</td>
</tr>
<tr>
<td class="Lrule" align="center">Total ICH<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="center">20 (6.4%)</td>
<td align="center">48 (15.4%) 															</td>
<td class="Rrule" align="center">&lt;0.01</td>
</tr>
<tr>
<td class="Lrule" align="center">Symptomatic</td>
<td align="center">4 (1.3%)</td>
<td align="center">25 (8.0%)</td>
<td class="Rrule" align="center">&lt;0.01</td>
</tr>
<tr>
<td class="Lrule" align="center">Asymptomatic</td>
<td align="center">16 (5.1%)</td>
<td align="center">23 (7.4%) 															</td>
<td class="Rrule" align="center">0.32</td>
</tr>
<tr>
<td class="Lrule" align="center">Symptomatic <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial Hemorrhage</span> within 36 hours</td>
<td align="center">2 (0.6%)</td>
<td align="center">20 (6.4%) 															</td>
<td class="Rrule" align="center">&lt;0.01</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">New <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span> (3-months)</td>
<td align="center">17 (5.4%)</td>
<td align="center">18 (5.8%) 															</td>
<td class="Rrule" align="center">1.00</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events other than <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> were noted in the studies of AIS and were consistent with the general safety profile of Activase.  In Studies 1 and 2, the frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requiring red blood cell transfusions was 6.4% for Activase-treated patients compared to 3.8% for placebo (p = 0.19).</p>
<p>Although exploratory analyses of Studies 1 and 2 suggest that severe neurological deficit (National Institutes of Health <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Scale [NIHSS &gt; 22]) at presentation was associated with an increased risk of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, efficacy results suggest a reduced but still favorable clinical outcome for these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> (AMI)</span></p>
<p>For the 3-hour infusion regimen in the treatment of AMI, the incidence of significant internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (estimated as &gt; 250 mL blood loss) has been reported in studies in over 800 patients (<a href="#table4">Table 4</a>).  These data do not include patients treated with the Activase accelerated infusion.</p>
<a name="table4"></a><table width="55%">
<caption><span>Table 4 Incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> in 3-Hour Infusion in AMI Patients</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="40%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Rrule" align="center">Total Dose  ≤100 mg</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Gastrointestinal</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">Genitourinary</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule" align="left">Retroperitoneal</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Gingival</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
</tbody>
</table>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> in AMI patients treated with Activase is presented in <a href="#table5">Table 5</a>.</p>
<a name="table5"></a><table width="75%">
<caption><span>Table 5 Incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial Hemorrhage</span> in AMI Patients</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom">Dose</th>
<th align="center" valign="bottom">Number of Patients</th>
<th class="Rrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial Hemorrhage</span> (%)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">100 mg, 3-hour</td>
<td align="center">3272</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr>
<td class="Lrule" align="left">≤ 100 mg, accelerated</td>
<td align="center">10,396</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr>
<td class="Lrule" align="left">150 mg</td>
<td align="center">1779</td>
<td class="Rrule" align="center">1.3</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">1-1.4 mg/kg</td>
<td align="center">237</td>
<td class="Rrule" align="center">0.4</td>
</tr>
</tbody>
</table>
<p>A dose of 150 mg or greater should not be used in the treatment of AMI because it has been associated with an increase in intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE)</span></p>
<p>For <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">acute massive pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events were consistent with the general safety profile observed with Activase treatment of AMI patients receiving the 3-hour infusion regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Allergic-type reactions, e.g., <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported.  When such reactions occur, they usually respond to conventional therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2     Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Activase.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  These reactions are frequent sequelae of the underlying disease, and the effect of Activase on the incidence of these events is unknown.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics">Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span>:</span> <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Cerebral edema</span>, cerebral herniation, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, new <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>.  These events may be life threatening and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span>:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, recurrent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial reinfarction</span>, <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span>, <span class="product-label-link" type="condition" conceptid="4122762" conceptname="Electromechanical dissociation">electromechanical dissociation</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="443962" conceptname="Mitral valve regurgitation">mitral regurgitation</span>, <span class="product-label-link" type="condition" conceptid="318450" conceptname="Cardiac tamponade">cardiac tamponade</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.  These events may be life threatening and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> have also been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span>:</span>  Pulmonary reembolization, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.  These events may be life threatening and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> has also been reported.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">The interaction of Activase with other cardioactive or cerebroactive drugs has not been studied.  Anticoagulants and antiplatelet drugs increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> if administered prior to, during, or after Activase therapy.</p>
<p>In the post-marketing setting, there have been reports of orolingual <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C</p>
<p>Activase is embryocidal in rabbits when intravenously administered in doses of approximately two times (3 mg/kg) the human dose for AMI.  No maternal or fetal toxicity was evident at 0.65 times (1 mg/kg) the human dose in pregnant rats and rabbits dosed during the period of organogenesis.  There are no adequate and well-controlled studies in pregnant women.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known whether Activase is excreted in human milk.  Many drugs are excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness of Activase in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1"></a><p></p>
<p class="First"><span class="Italics">Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span></span></p>
<p>In exploratory, multivariate analyses of Studies 1 and 2,  age greater than 77 years was one of several interrelated baseline characteristics associated with an increased risk of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>. Efficacy results suggest a reduced but still favorable clinical outcome for Activase-treated elderly <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span></span></p>
<p>In a large trial of accelerated-infusion Activase that enrolled 41,021 patients with AMI to one of four thrombolytic regimens <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>, patients over 75 years of age, a predefined subgroup, comprised 12% of enrollment.  In these patients, the incidence of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was 4.0% for the Activase accelerated infusion group, 2.8% for streptokinase IV [SK (IV)], and 3.2% for streptokinase SQ [SK (SQ)].  The incidence of combined 30-day mortality or nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was 20.6% for accelerated infusion of Activase, 21.5% for SK (IV), and 22.0% for SK (SQ).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Activase is a tissue <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator produced by recombinant DNA technology.  It is a sterile, purified glycoprotein of 527 amino acids.  It is synthesized using the complementary DNA (cDNA) for natural human tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator obtained from a human melanoma cell line.  Activase is a sterile, white to off-white, lyophilized powder for intravenous administration after reconstitution with Sterile Water for Injection, USP.</p>
<a name="table6"></a><table width="75%">
<caption><span>Table 6 Quantitative Composition of the Lyophilized Product</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th align="center">100 mg Vial</th>
<th class="Rrule" align="center">50 mg Vial</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Alteplase</td>
<td align="center">100 mg (58 million IU)</td>
<td class="Rrule" align="center">50 mg (29 million IU)</td>
</tr>
<tr>
<td class="Lrule" align="left">L-Arginine</td>
<td align="center">3.5 g</td>
<td class="Rrule" align="center">1.7 g</td>
</tr>
<tr>
<td class="Lrule" align="left">Phosphoric Acid</td>
<td align="center">1 g</td>
<td class="Rrule" align="center">0.5 g</td>
</tr>
<tr>
<td class="Lrule" align="left">Polysorbate 80</td>
<td align="center">10 mg</td>
<td class="Rrule" align="center">5 mg</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Vacuum</td>
<td align="center">No</td>
<td class="Rrule" align="center">Yes</td>
</tr>
</tbody>
</table>
<p>Biological potency is determined by an in vitro clot lysis assay and is expressed in International Units (IU).</p>
<p>The reconstituted preparation results in a colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow transparent solution containing Activase 1 mg/mL at approximately pH 7.3.  The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of this solution is approximately 215 mOsm/kg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Alteplase is a serine protease responsible for fibrin-enhanced conversion of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> to plasmin.  It produces limited conversion of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> in the absence of fibrin.</p>
<p>When introduced into the systemic circulation at pharmacologic concentration, alteplase binds to fibrin in a thrombus and converts the entrapped <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> to plasmin.  This initiates local <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> with limited systemic proteolysis.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-10.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<p class="First">Following administration of 100 mg Activase, there is a decrease (16%-36%) in circulating fibrinogen.  In a controlled trial, 8 of 73 patients (11%) receiving Activase (1.25 mg/kg body weight over 3 hours) experienced a decrease in fibrinogen to below 100 mg/dL.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-10.3"></a><p></p>
<h2>12.3	Pharmacokinetics </h2>
<p class="First">Alteplase in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (AMI) patients is rapidly cleared from the plasma with an initial half-life of less than 5 minutes.  There is no difference in the dominant initial plasma half-life between the 3-hour and accelerated regimens for AMI.  The plasma clearance of alteplase is 380-570 mL/min, primarily mediated by the liver.  The initial volume of distribution approximates plasma volume.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential or the effect on fertility.  Short-term studies, which evaluated tumorigenicity of Activase and effect on tumor <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> in rodents, were negative.</p>
<p>Studies to determine mutagenicity (Ames test) and chromosomal aberration assays in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> were negative at all concentrations tested.  Cytotoxicity, as reflected by a decrease in mitotic index, was evidenced only after prolonged exposure and only at the highest concentrations tested.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-12.1"></a><p></p>
<h2>14.1   Acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic Stroke</span> (AIS)</h2>
<p class="First">Two placebo-controlled, double-blind trials (Studies 1 and 2) were conducted in patients with AIS.  Both studies enrolled patients with measurable neurological deficit who could complete screening and begin study treatment within 3 hours from symptom onset.  A cranial computerized tomography (CT) scan was performed prior to treatment to rule out the presence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.  Blood pressure was actively controlled (185/110 mm Hg or lower) for 24 hours.</p>
<p>Patients were randomized (1:1) to receive either 0.9 mg/kg Activase (maximum of 90 mg) or placebo.  Activase was administered as a 10% initial IV bolus over 1 minute followed by continuous IV infusion of the remainder over 60 minutes.  Study treatment was initiated prior to the availability of coagulation study results in patients without recent use of oral anticoagulants and/or heparin and was discontinued if the pretreatment <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) was greater than 15 seconds or the <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT) was elevated.  Patients with prior aspirin use were included.  Administration of anticoagulants and antiplatelet agents was prohibited for the first 24 hours following symptom onset.</p>
<p>Study 1 (n=291) evaluated neurological improvement at 24 hours after <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> onset.  The primary endpoint, the proportion of patients with a 4 point or greater improvement in the National Institutes of Health <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Scale (NIHSS) score or complete recovery (NIHSS score of 0), was not significantly different between treatment groups.  A prespecified secondary analysis suggested improved 3-month outcome associated with Activase treatment using the following <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> assessment scales:  Barthel Index, Modified Rankin Scale, Glasgow Outcome Scale, and the NIHSS.</p>
<p>Study 2 (n=333) assessed clinical outcome at 3 months.  A favorable outcome was defined as minimal or no <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> using four <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> assessment scales:  Barthel Index (score of 95 or greater), Modified Rankin Scale (score of 1 or less), Glasgow Outcome Scale (score of 1), and NIHSS (score of 1 or less).  The results comparing Activase- and placebo-treated patients for the four outcome scales together (Generalized Estimating Equations) and individually are presented in <a href="#table7">Table 7</a>.  In this study, depending upon the scale, the favorable outcome of minimal or no <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> occurred in at least 11 per 100 more patients treated with Activase than those receiving placebo.  Study results demonstrated consistent functional and neurological improvement within all four <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> scales as indicated by median scores.  These results were consistent with the 3-month outcome treatment effects observed in Study 1.</p>
<a name="table7"></a><table width="90%">
<caption><span>Table 7 Study 2 Three-Month Efficacy Outcomes</span></caption>
<col align="center" valign="top" width="35%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<thead>
<tr class="First">
<th class="Lrule" align="center" rowspan="2" valign="bottom">Analysis</th>
<th class="Botrule Rrule" align="center" colspan="5">Frequency of Favorable Outcome<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th align="center" valign="bottom">Placebo<br>(n=165)</th>
<th align="center" valign="bottom">Activase<br>(n=168)</th>
<th align="center" valign="bottom">Absolute Difference<br>(95% CI)</th>
<th align="center" valign="bottom">Odds Ratio<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a><br>(95% Cl)</th>
<th class="Rrule" align="center" valign="bottom">p-Value<a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Favorable Outcome is defined as recovery with minimal or no <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Value greater than 1 indicates odds of recovery in favor of Activase treatment.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>p-Value for Odds Ratio is from Generalized Estimating Equations with logit link.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="center">Generalized Estimating Equations (Multivariate)</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">-</td>
<td align="center">1.71<br>(1.15, 2.56) 											</td>
<td class="Rrule" align="center">0.02</td>
</tr>
<tr>
<td class="Lrule" align="center">Barthel Index</td>
<td align="center">37.6%</td>
<td align="center">50.0%</td>
<td align="center">12.4%<br>(3.0, 21.9)</td>
<td align="center">1.66<br>(1.07, 2.57) 											</td>
<td class="Rrule" align="center">0.02</td>
</tr>
<tr>
<td class="Lrule" align="center">Modified Rankin Scale</td>
<td align="center">26.1%</td>
<td align="center">38.7%</td>
<td align="center">12.6%<br>(3.7, 21.6)</td>
<td align="center">1.79<br>(1.12, 2.85) 											</td>
<td class="Rrule" align="center">0.02</td>
</tr>
<tr>
<td class="Lrule" align="center">Glasgow Outcome Scale</td>
<td align="center">31.5%</td>
<td align="center">44.0%</td>
<td align="center">12.5%<br>(3.3, 21.8)</td>
<td align="center">1.71<br>(1.09, 2.68) 											</td>
<td class="Rrule" align="center">0.02</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">NIHSS</td>
<td align="center">20.0%</td>
<td align="center">31.0%</td>
<td align="center">11.0%<br>(2.6, 19.3)</td>
<td align="center">1.79<br>(1.06, 2.96) 											</td>
<td class="Rrule" align="center">0.02</td>
</tr>
</tbody>
</table>
<p>In a prespecified subgroup analysis of patients receiving aspirin prior to onset of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> symptoms, the favorable outcome for Activase-treated patients was preserved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-12.2"></a><p></p>
<h2>14.2	<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> (AMI)</h2>
<p class="First">Two Activase dose regimens have been studied in patients experiencing <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>].</span>  The comparative efficacy of these two regimens has not been evaluated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Italics">Accelerated Infusion in AMI Patients</span></p>
<p>Accelerated infusion of Activase was studied in an international, multi-center trial that randomized 41,021 patients with AMI to four thrombolytic regimens (Study 3).  Entry criteria included onset of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> within 6 hours of treatment and ST-segment elevation of ECG.  The four treatment regimens included accelerated infusion of Activase (≤100 mg over 90 minutes) plus intravenous (IV) heparin (n = 10,396); Streptokinase (1.5 million units over 60 minutes) plus IV heparin (SK [IV], n =10,410); Streptokinase plus subcutaneous (SQ) heparin (SK [SQ] n= 9841).  A fourth regimen combined Activase and Streptokinase (n =10,374).  All patients received 160 mg chewable aspirin administered as soon as possible, followed by 160-325 mg daily.  Bolus IV heparin 5000 U was initiated as soon as possible, followed by a 1000 U/hour continuous IV infusion for at least 48 hours; subsequent heparin therapy was at the physician's discretion.  Heparin SQ 12,500 U was administered 4 hours after initiation of SK therapy, followed by 12,500 U twice daily for 7 days or until discharge, whichever came first.  Many of the patients randomized to receive SQ heparin received some IV heparin, usually in response to recurrent <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> and/or the need for a medical procedure.  Some received IV heparin on arrival to the emergency room prior to enrollment and randomization.</p>
<p>Key results from Study 3 are shown in <a href="#table8">Table 8</a>.  The incidence of 30-day mortality for Activase accelerated infusion was 1.0% lower than for either Streptokinase plus heparin regimen.  The incidence of combined 30-day mortality or nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> for the Activase accelerated infusion was 1.0% lower than for SK (IV) and 0.8% lower than for SK (SQ).</p>
<a name="table8"></a><table width="75%">
<caption><span>Table 8 Efficacy and Safety Results for Study 3</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom">Event</th>
<th align="center" valign="bottom">Accelerated Activase</th>
<th align="center" valign="bottom">SK (IV)</th>
<th align="center" valign="bottom">p-Value<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</th>
<th align="center" valign="bottom">SK (SQ)</th>
<th class="Rrule" align="center" valign="bottom">p-Value<a href="#footnote-6" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Two-tailed p-value is for comparison of Accelerated Activase to the respective SK control arm.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">30-Day Mortality</td>
<td align="center">6.3%</td>
<td align="center">7.3%</td>
<td align="center">0.003</td>
<td align="center">7.3%</td>
<td class="Rrule" align="center">0.007</td>
</tr>
<tr>
<td class="Lrule" align="left">30-Day Mortality<br>or Nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td align="center">7.2%</td>
<td align="center">8.2%</td>
<td align="center">0.006</td>
<td align="center">8.0%</td>
<td class="Rrule" align="center">0.036</td>
</tr>
<tr>
<td class="Lrule" align="left">24-Hour Mortality</td>
<td align="center">2.4%</td>
<td align="center">2.9%</td>
<td align="center">0.009</td>
<td align="center">2.8%</td>
<td class="Rrule" align="center">0.029</td>
</tr>
<tr>
<td class="Lrule" align="left">Any <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td align="center">1.6%</td>
<td align="center">1.4%</td>
<td align="center">0.32</td>
<td align="center">1.2%</td>
<td class="Rrule" align="center">0.03</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Intracerebral Hemorrhage</span></td>
<td align="center">0.7%</td>
<td align="center">0.6%</td>
<td align="center">0.22</td>
<td align="center">0.5%</td>
<td class="Rrule" align="center">0.02</td>
</tr>
</tbody>
</table>
<p>Subgroup analysis of patients by age, infarct location, time from symptom onset to thrombolytic treatment, and treatment in the U.S. or elsewhere showed consistently lower 30-day mortality on Activase.</p>
<p>For patients who were over 75 years of age, a predefined subgroup consisting of 12% of patients enrolled, the incidence of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was 4.0% for the Activase accelerated infusion group, 2.8% for SK (IV), and 3.2% for SK (SQ); the incidence of combined 30-day mortality or nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was 20.6% for accelerated infusion of Activase, 21.5% for SK (IV), and 22.0% for SK (SQ).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.2"></a><p></p>
<p class="First"><span class="Italics">3-Hour Infusion in AMI Patients</span></p>
<p>In a double-blind, randomized trial (n = 138) comparing 3-hour infusion of Activase to placebo (Study 4), patients infused with Activase within 4 hours of onset of symptoms experienced improved left ventricular function at Day 10 compared to the placebo group, when <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> was measured by gated blood pool scan (53.2% vs. 46.4%, p =0.018).  Relative to baseline (Day 1) values, the net changes in <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> were + 3.6% and -4.7% for the treated and placebo groups, respectively (p=0.0001).  The treated group had a reduced incidence of clinical <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (14%) compared to the placebo group (33%) (p = 0.009).</p>
<p>In a double-blind, randomized trial (n =5013) comparing 3-hour infusion of Activase to placebo (Study 5), patients infused with Activase within 5 hours of AMI symptom onset experienced improved 30-day survival compared to the placebo arm.  At 1 month, the overall mortality rates were 7.2% for the Activase group and 9.8% for the placebo group (p = 0.001).  At 6 months, the overall mortality rate for Activase-treated patients was 10.4% compared to the placebo arm (13.1%, p= 0.008).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-12.3"></a><p></p>
<h2>14.3	<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Acute Massive Pulmonary Embolism</span> (PE)</h2>
<p class="First">Study 6 was a comparative randomized trial (n =45) in which 59% of patients (n =22) treated with Activase (100 mg over 2 hours) experienced moderate or marked lysis of pulmonary emboli when assessed by pulmonary angiography 2 hours after treatment initiation.  Activase-treated patients also experienced a significant reduction in <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>-induced <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> within 2 hours of treatment (p=0.003).  Pulmonary perfusion at 24 hours, as assessed by radionuclide scan, was significantly improved (p= 0.002).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-13.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">Activase is supplied as a sterile, lyophilized powder in 50 mg vials containing vacuum and in 100 mg vials without vacuum.</p>
<p>Each 50 mg Activase vial (29 million IU) is packaged with diluent for reconstitution (50 mL Sterile Water for Injection, USP):  NDC 50242-044-13.</p>
<p>Each 100 mg Activase vial (58 million IU) is packaged with diluent for reconstitution (100 mL Sterile Water for Injection, USP), and one transfer device:  NDC 50242-085-27.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-13.2"></a><p></p>
<h2>16.2	Stability and Storage</h2>
<p class="First">Store lyophilized Activase at controlled room temperature not to exceed 30°C (86°F), or under refrigeration (2-8°C/36-46°F).  Protect the lyophilized material during extended storage from excessive exposure to light.  If stored between 2-30°C (36-86°F), Activase may be used within 8 hours following reconstitution.  Discard any unused solution after administration is complete.</p>
<p>Do not use beyond the expiration date stamped on the vial.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Following Activase administration, patients are at increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> internally or externally.  Advise patients to contact a health-care professional if they experience symptoms or signs consistent with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (e.g., unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, pink or brown urine, red or black or <span class="product-label-link" type="condition" conceptid="4103703" conceptname="Melena">tarry stools</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> blood or blood that looks like coffee grounds), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Activase<span class="Sup">®</span> (Alteplase)</span><br>Manufactured by:<br><span class="Bold">Genentech, Inc.</span><br>A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA <br>94080-4990</p>
<p>Activase<span class="Bold"><span class="Sup">®</span></span> is a registered trademark of Genentech, Inc.<br><span class="Sup">©</span>2015 Genentech, Inc.</p>
<p>Representative sample of labeling (see the <a href="#S16">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Kit Carton - 50 mg</span></p>
<p>NDC 50242-044-13</p>
<p><span class="Bold">ALTEPLASE <br>ACTIVASE<span class="Sup">®</span></span></p>
<p><span class="Bold">for intravenous use</span></p>
<p><span class="Bold">50 mg</span> (29 million IU)</p>
<p><span class="Bold">a tissue <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator</span></p>
<p>10136622</p>
<p><span class="Bold">Genentech</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Kit Carton - 50 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c669f77c-fa48-478b-a14b-80b20a0139c2&amp;name=activase-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Kit Carton - 100 mg</span></p>
<p>NDC 50242-085-27</p>
<p><span class="Bold">ALTEPLASE <br>ACTIVASE<span class="Sup">®</span></span></p>
<p><span class="Bold">for intravenous use</span></p>
<p><span class="Bold">100 mg</span> (58 million IU)</p>
<p><span class="Bold">a tissue <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator</span></p>
<p>10136646</p>
<p><span class="Bold">Genentech</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Kit Carton - 100 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c669f77c-fa48-478b-a14b-80b20a0139c2&amp;name=activase-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACTIVASE 		
					</strong><br><span class="contentTableReg">alteplase kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-044</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-044-13</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">50 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">50 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ACTIVASE 		
					</strong><br><span class="contentTableReg">alteplase injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALTEPLASE</strong> (ALTEPLASE) </td>
<td class="formItem">ALTEPLASE</td>
<td class="formItem">50 mg  in 50 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ARGININE</strong></td>
<td class="formItem">1.7 g  in 50 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHOSPHORIC ACID</strong></td>
<td class="formItem">0.5 g  in 50 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">4 mg  in 50 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103172</td>
<td class="formItem">11/13/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water injection</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem">50 mL  in 50 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103172</td>
<td class="formItem">11/13/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103172</td>
<td class="formItem">11/13/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACTIVASE 		
					</strong><br><span class="contentTableReg">alteplase kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-085</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-085-27</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">100 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ACTIVASE 		
					</strong><br><span class="contentTableReg">alteplase injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALTEPLASE</strong> (ALTEPLASE) </td>
<td class="formItem">ALTEPLASE</td>
<td class="formItem">100 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ARGININE</strong></td>
<td class="formItem">3.5 g  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHOSPHORIC ACID</strong></td>
<td class="formItem">1 g  in 100 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">11 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103172</td>
<td class="formItem">11/13/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water injection</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem">100 mL  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103172</td>
<td class="formItem">11/13/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103172</td>
<td class="formItem">11/13/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genentech, Inc.
							(080129000)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Genentech, Inc. (080129000)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (SSF)</td>
<td class="formItem"></td>
<td class="formItem">080129000</td>
<td class="formItem">ANALYSIS(50242-044, 50242-085), MANUFACTURE(50242-044, 50242-085)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (Vacaville)</td>
<td class="formItem"></td>
<td class="formItem">004074162</td>
<td class="formItem">ANALYSIS(50242-044, 50242-085)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (Hillsboro)</td>
<td class="formItem"></td>
<td class="formItem">833220176</td>
<td class="formItem">ANALYSIS(50242-044, 50242-085), PACK(50242-044, 50242-085)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f23e5c78-91b0-4c5c-8c2b-53207bb2e765</div>
<div>Set id: c669f77c-fa48-478b-a14b-80b20a0139c2</div>
<div>Version: 3</div>
<div>Effective Time: 20150224</div>
</div>
</div> <div class="DistributorName">Genentech, Inc.</div></p>
</body></html>
